Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ABBOTT INDIA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ABBOTT INDIA AUROBINDO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 17.8 47.8 37.3% View Chart
P/BV x 3.9 15.6 24.7% View Chart
Dividend Yield % 0.3 0.4 61.9%  

Financials

 AUROBINDO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
ABBOTT INDIA
Mar-19
AUROBINDO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs8308,834 9.4%   
Low Rs5275,458 9.7%   
Sales per share (Unadj.) Rs333.91,731.1 19.3%  
Earnings per share (Unadj.) Rs40.4211.9 19.0%  
Cash flow per share (Unadj.) Rs51.8219.9 23.5%  
Dividends per share (Unadj.) Rs2.5065.00 3.8%  
Dividend yield (eoy) %0.40.9 40.5%  
Book value per share (Unadj.) Rs237.1945.2 25.1%  
Shares outstanding (eoy) m585.9121.25 2,757.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.04.1 49.2%   
Avg P/E ratio x16.833.7 49.9%  
P/CF ratio (eoy) x13.132.5 40.3%  
Price / Book Value ratio x2.97.6 37.9%  
Dividend payout %6.230.7 20.2%   
Avg Mkt Cap Rs m397,569151,848 261.8%   
No. of employees `00017.93.5 512.3%   
Total wages/salary Rs m25,8494,356 593.4%   
Avg. sales/employee Rs Th10,956.910,555.5 103.8%   
Avg. wages/employee Rs Th1,447.71,249.9 115.8%   
Avg. net profit/employee Rs Th1,324.31,292.2 102.5%   
INCOME DATA
Net Sales Rs m195,63636,786 531.8%  
Other income Rs m1,5531,133 137.1%   
Total revenues Rs m197,18937,919 520.0%   
Gross profit Rs m39,5196,047 653.5%  
Depreciation Rs m6,680169 3,947.7%   
Interest Rs m2,62623 11,671.1%   
Profit before tax Rs m31,7676,989 454.6%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2692,485 292.5%   
Profit after tax Rs m23,6454,503 525.1%  
Gross profit margin %20.216.4 122.9%  
Effective tax rate %22.935.6 64.3%   
Net profit margin %12.112.2 98.7%  
BALANCE SHEET DATA
Current assets Rs m153,64527,610 556.5%   
Current liabilities Rs m120,4298,569 1,405.4%   
Net working cap to sales %17.051.8 32.8%  
Current ratio x1.33.2 39.6%  
Inventory Days Days13560 224.5%  
Debtors Days Days6427 232.5%  
Net fixed assets Rs m103,9091,057 9,831.6%   
Share capital Rs m586213 275.7%   
"Free" reserves Rs m138,32219,873 696.0%   
Net worth Rs m138,90820,086 691.6%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54429,409 899.5%  
Interest coverage x13.1311.6 4.2%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.3 59.1%   
Return on assets %9.915.4 64.5%  
Return on equity %17.022.4 75.9%  
Return on capital %23.834.9 68.3%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,316369 26,375.9%   
Fx outflow Rs m40,5894,918 825.2%   
Net fx Rs m56,727-4,549 -1,246.9%   
CASH FLOW
From Operations Rs m16,2204,991 325.0%  
From Investments Rs m-28,768-2,570 1,119.4%  
From Financial Activity Rs m19,191-1,428 -1,343.9%  
Net Cashflow Rs m6,656993 670.1%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.0 7.9 100.6%  
FIIs % 27.7 0.1 27,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.1 59.6%  
Shareholders   69,601 18,270 381.0%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 470 Points Lower; Tata Motors & Tata Steel Fall 6%(Closing)

Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 18, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS